Human Reproduction Department. Women's Health Reference Center - Pérola Byington Hospital, São Paulo, SP, Brazil.
Gynecology and Obstetrics Department, Botucatu Medical School, UNESP - Universidade Estadual de São Paulo, Botucatu, SP, Brazil.
JBRA Assist Reprod. 2020 Jul 14;24(3):257-264. doi: 10.5935/1518-0557.20200002.
Patients submitted to oncological fertility preservation with letrozole and gonadotropins seem to present a higher rate of immature oocytes and lower fertilization rates in comparison to infertile patients submitted to IVF cycles with gonadotropins. The aim of this study was to evaluate the influence of letrozole on oocyte morphology in patients with breast cancer submitted to fertility preservation.
Retrospective analysis performed at a public tertiary hospital in São Paulo, Brazil. The oocytes were retrieved from patients with breast cancer undergoing fertility preservation (n=69), and from infertile women undergoing in vitro fertilization (n=92). We evaluated 750 oocytes obtained from breast cancer patients submitted to ovarian stimulation with letrozole and gonadotropins, and 699 oocytes from patients without breast cancer submitted to ovarian stimulation for in vitro fertilization with gonadotropins only due to male factor infertility. The mature oocytes retrieved were analyzed for the presence of refractile bodies, ooplasm color and regularity, central granulation degree, cortical granules, zona pellucida staining and regularity, perivitelline space, presence of vacuoles or abnormal smooth-surfaced endoplasmic reticle and oocyte retraction.
There was a higher incidence of alterations in oocyte morphology in the letrozole group when compared to the control group: increased perivitelline space (p=0.007), irregular zona pellucida (p<0.001), refractile bodies (p<0.001), dark ooplasm (p<0.001), granular ooplasm (p<0.001), irregular ooplasm (p<0.001) and dense central granulation (p<0.001).
Letrozole is a risk factor for worse oocyte morphology. However, the clinical impact of ovarian stimulation protocol with combined use of gonadotropins and letrozole for fertility preservation remains unclear in this setting. These data underline the importance of establishing the predictive potential of morphological dimorphisms of human oocytes in IVF outcomes.
与接受单纯性腺激素刺激的不孕患者相比,接受来曲唑和性腺激素进行肿瘤患者生育力保存的患者的未成熟卵母细胞率更高,受精率更低。本研究旨在评估来曲唑对接受生育力保存的乳腺癌患者卵母细胞形态的影响。
这是在巴西圣保罗的一家公立三级医院进行的回顾性分析。从接受生育力保存的乳腺癌患者(n=69)和接受体外受精的不孕妇女(n=92)中获取卵母细胞。我们评估了 69 例接受来曲唑和性腺激素卵巢刺激的乳腺癌患者的 750 个卵母细胞和 699 例因男性因素不孕而仅接受性腺激素卵巢刺激进行体外受精的无乳腺癌患者的 699 个卵母细胞。分析了从卵巢刺激中获得的成熟卵母细胞,以评估其反射体、卵浆颜色和规则性、中央颗粒程度、皮质颗粒、透明带染色和规则性、卵周隙、空泡或异常光滑内质网的存在以及卵母细胞回缩。
与对照组相比,来曲唑组卵母细胞形态改变的发生率更高:卵周隙增加(p=0.007)、透明带不规则(p<0.001)、反射体(p<0.001)、暗卵浆(p<0.001)、颗粒状卵浆(p<0.001)、不规则卵浆(p<0.001)和密集的中央颗粒(p<0.001)。
来曲唑是卵母细胞形态恶化的一个危险因素。然而,在这种情况下,联合使用性腺激素和来曲唑进行卵巢刺激方案对生育力保存的临床影响仍不清楚。这些数据强调了在体外受精结局中确定人类卵母细胞形态二态性预测潜力的重要性。